2026-04-17T08:10:09Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1758032025-12-05T11:58:06Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT author Alcibar, Olwen Leaman author Nadal, Ernest author Romero Palomar, Inmaculada author Navarro Martín, Arturo 2021-03-26T10:29:16Z2021-03-26T10:29:16Z2021-01-012021-03-24T07:43:51Z Despite adequate treatment, 50% of stage III locally advanced inoperable non-small cell lung cancer (NSCLC) patients have a locoregional relapse. Local control on early stages on the contrary, is as high as 85-90% with stereotactic body radiotherapy (SBRT). The addition of SBRT to conventional chemoradiation or its use in monotherapy in stage III NSCLC is a novel strategy to decrease local failure that has been explored by various authors. This is a systematic review of studies using SBRT in inoperable stage III NSCLC. Search results obtained 141 articles of which only 6 original studies were pointed as relevant. Three of these studies were prospective, of which 2 were phase I dose-scalation studies and remaining 3 were retrospective. In summary, SBRT outcomes on 134 patients were included. Median dose in the SBRT treatment was 22.5 Gy in 2 to 7 fractions. Obtained global toxicity was 3.7% grade 5 and 14.17% grade 3. Dose-escalation studies proposed a 2 fraction SBRT schedule of 20-24 Gy, obtaining a 78% local control rate at 1 year and an OS of 67%. Initial improvement in local control with this innovative therapeutic strategy has led to ongoing phase II and III clinical trials that will evaluate the efficiency of SBRT in stage III NSCLC clinical scenario. cc by-nc-nd (c) Translational Lung Cancer Research, 2021 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess Càncer de pulmó Radioteràpia Lung cancer Radiotherapy Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion